182 related articles for article (PubMed ID: 34408227)
21. Overexpression of mir-129-1, miR-146b, mir-183, and mir-197 in follicular thyroid carcinoma and adenoma tissues.
Sheikholeslami S; Shabani N; Shivaee S; Tavangar SM; Yeganeh M; Hedayati M; Lotfi J; Gholami H
Mol Cell Probes; 2020 Jun; 51():101536. PubMed ID: 32081771
[TBL] [Abstract][Full Text] [Related]
22. Expression of the embryonic morphogen Nodal in differentiated thyroid carcinomas: Immunohistochemistry assay in tissue microarray and The Cancer Genome Atlas data analysis.
Chai YJ; Kim YA; Jee HG; Yi JW; Jang BG; Lee KE; Park YJ; Youn YK
Surgery; 2014 Dec; 156(6):1559-67; discussion 1567-8. PubMed ID: 25456955
[TBL] [Abstract][Full Text] [Related]
23. Proteotypic Differences of Follicular-Patterned Thyroid Neoplasms.
Huang D; Zhang H; Li L; Ge W; Liu W; Dong Z; Gao J; Yao N; Fu W; Huang L; Guo T; Sun Y; Teng X
Front Endocrinol (Lausanne); 2022; 13():854611. PubMed ID: 35923625
[TBL] [Abstract][Full Text] [Related]
24. NR2F1-AS1 regulated miR-423-5p/SOX12 to promote proliferation and invasion of papillary thyroid carcinoma.
Yang C; Liu Z; Chang X; Xu W; Gong J; Chai F; Cui D
J Cell Biochem; 2020 Feb; 121(2):2009-2018. PubMed ID: 31692033
[TBL] [Abstract][Full Text] [Related]
25. Linc00941 Is a Novel Transforming Growth Factor β Target That Primes Papillary Thyroid Cancer Metastatic Behavior by Regulating the Expression of Cadherin 6.
Gugnoni M; Manicardi V; Torricelli F; Sauta E; Bellazzi R; Manzotti G; Vitale E; de Biase D; Piana S; Ciarrocchi A
Thyroid; 2021 Feb; 31(2):247-263. PubMed ID: 32495722
[No Abstract] [Full Text] [Related]
26. Degradation of extracellular matrix by metastatic follicular thyroid carcinoma cell lines: role of the plasmin activation system.
Smit JW; van der Pluijm G; Romijn HA; Löwik CW; Morreau H; Goslings BM
Thyroid; 1999 Sep; 9(9):913-9. PubMed ID: 10524570
[TBL] [Abstract][Full Text] [Related]
27. Long Noncoding RNA GAS5 Targeting miR-221-3p/Cyclin-Dependent Kinase Inhibitor 2B Axis Regulates Follicular Thyroid Carcinoma Cell Cycle and Proliferation.
Liu Y; Li YF; Liu J; Deng ZG; Zeng L; Zhou WB
Pathobiology; 2021; 88(4):289-300. PubMed ID: 34130294
[TBL] [Abstract][Full Text] [Related]
28. Characterization of somatostatin receptors (SSTRs) expression and antiproliferative effect of somatostatin analogues in aggressive thyroid cancers.
Carmona Matos DM; Jang S; Hijaz B; Chang AW; Lloyd RV; Chen H; Jaskula-Sztul R
Surgery; 2019 Jan; 165(1):64-68. PubMed ID: 30415874
[TBL] [Abstract][Full Text] [Related]
29. [Mutation of RAS gene in follicular-differentiated thyroid tumors and its significance].
Liu LP; Hao JY; Pan H; Wang C; Yue P
Zhonghua Bing Li Xue Za Zhi; 2020 Mar; 49(3):256-261. PubMed ID: 32187898
[No Abstract] [Full Text] [Related]
30. How to define follicular thyroid carcinoma?
Schmid KW; Farid NR
Virchows Arch; 2006 Apr; 448(4):385-93. PubMed ID: 16506015
[TBL] [Abstract][Full Text] [Related]
31. HGF/C-MET system pathways in benign and malignant histotypes of thyroid nodules: an immunohistochemical characterization.
Ruggeri RM; Vitarelli E; Barresi G; Trimarchi F; Benvenga S; Trovato M
Histol Histopathol; 2012 Jan; 27(1):113-21. PubMed ID: 22127603
[TBL] [Abstract][Full Text] [Related]
32. Immunohistochemical distinction of follicular thyroid adenomas and follicular carcinomas.
Bryson PC; Shores CG; Hart C; Thorne L; Patel MR; Richey L; Farag A; Zanation AM
Arch Otolaryngol Head Neck Surg; 2008 Jun; 134(6):581-6. PubMed ID: 18559722
[TBL] [Abstract][Full Text] [Related]
33. Integrated analysis identifying new lncRNA markers revealed in ceRNA network for tumor recurrence in papillary thyroid carcinoma and build of nomogram.
Chen F; Li Z; Deng C; Yan H
J Cell Biochem; 2019 Dec; 120(12):19673-19683. PubMed ID: 31271223
[TBL] [Abstract][Full Text] [Related]
34. LncRNA PROX1-AS1 promotes proliferation, invasion, and migration in papillary thyroid carcinoma.
Shen Y; Xia E; Bhandari A; Wang X; Guo G
Biosci Rep; 2018 Oct; 38(5):. PubMed ID: 30061172
[TBL] [Abstract][Full Text] [Related]
35. Genome-Wide Expression Screening Discloses Long Noncoding RNAs Involved in Thyroid Carcinogenesis.
Liyanarachchi S; Li W; Yan P; Bundschuh R; Brock P; Senter L; Ringel MD; de la Chapelle A; He H
J Clin Endocrinol Metab; 2016 Nov; 101(11):4005-4013. PubMed ID: 27459529
[TBL] [Abstract][Full Text] [Related]
36. CCAT2 contributes to progression and treatment resistance of thyroid carcinoma.
Fu W; Wang XD; Ye JD; Jin J; Chen L; Qi QY
Eur Rev Med Pharmacol Sci; 2020 Dec; 24(23):12224-12231. PubMed ID: 33336741
[TBL] [Abstract][Full Text] [Related]
37. Targeted inhibition of long non-coding RNA H19 blocks anaplastic thyroid carcinoma growth and metastasis.
Zhang H; Yu Y; Zhang K; Liu X; Dai Y; Jiao X
Bioengineered; 2019 Dec; 10(1):306-315. PubMed ID: 31299871
[TBL] [Abstract][Full Text] [Related]
38. Mouse Model of Thyroid Cancer Progression and Dedifferentiation Driven by STRN-ALK Expression and Loss of p53: Evidence for the Existence of Two Types of Poorly Differentiated Carcinoma.
Nikitski AV; Rominski SL; Condello V; Kaya C; Wankhede M; Panebianco F; Yang H; Altschuler DL; Nikiforov YE
Thyroid; 2019 Oct; 29(10):1425-1437. PubMed ID: 31298630
[No Abstract] [Full Text] [Related]
39. Siglec-15 Silencing Inhibits Cell Proliferation and Promotes Cell Apoptosis by Inhibiting STAT1/STAT3 Signaling in Anaplastic Thyroid Carcinoma.
Hou X; Chen C; He X; Lan X
Dis Markers; 2022; 2022():1606404. PubMed ID: 35769818
[TBL] [Abstract][Full Text] [Related]
40. Molecular characterization of tumors meeting diagnostic criteria for the non-invasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP).
Pool C; Walter V; Bann D; Goldenberg D; Broach J; Hennessy M; Cottrill E; Washburn E; Williams N; Crist H; Imamura Y; Warrick JI
Virchows Arch; 2019 Mar; 474(3):341-351. PubMed ID: 30645670
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
